Pembrolizumab: bei höherer PD-L1-Expression hoch effektiv
Crossref DOI link: https://doi.org/10.1007/s15004-019-6652-4
Published Online: 2019-09-05
Published Print: 2019-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schalhorn, Andreas
Text and Data Mining valid from 2019-09-01
Version of Record valid from 2019-09-01
Article History
First Online: 5 September 2019